Gasan dong, South Korea
Gasan dong, South Korea

Time filter

Source Type

DecisionDatabases.com offer Next Generation Sequencing (NGS) Market Research Report. This Report covers the complete Industry Outlook, Growth, Size, Share and Forecast Till 2022. Get Free Sample Copy of this Report @ http://www.decisiondatabases.com/contact/download-sample-11311 The report on global next generation sequencing (NGS) market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2015-2022. The market size in terms of revenue (USD MN) is calculated for the study period along with the details of the factors affecting the market growth (drivers and restraints). A glimpse of the major drivers and restraints affecting this market is mentioned below: Furthermore, the report quantifies the market share held by the major players of the industry and provides an in-depth view of the competitive landscape. This market is classified into different segments with detailed analysis of each with respect to geography for the study period 2015-2022. The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities. The report classifies the market into different segments based on technology, workflow, application and end-use. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market. Leading Segment in this market: By Technology - Targeted Sequencing And Resequencing By Application – HLA Testing By End –Use - Academic Research By Geography – North America The report also covers the complete competitive landscape of the worldwide market with company profiles of key players such as Illumina Incorporated, 454 Life Sciences, Agilent Technologies, Knome Inc., Genomatix Software GmbH, GATC Biotech Ag, Oxford Nanopore Technologies Ltd., Macrogen Inc., Life Technologies Corp., DNASTAR Inc., Biomatters Ltd., Life CLC Bio, BGI, Qiagen NV, Perkin Elmer, Inc., Pacific Bioscience, Inc. and Partek, Inc.. A detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments. For More Information about this Report: http://www.decisiondatabases.com/ip/11311-next-generation-sequencing-ngs-market-report 1. INTRODUCTION 2. EXECUTIVE SUMMARY 3. MARKET ANALYSIS 4. NEXT GENERATION SEQUENCING (NSG) MARKET ANALYSIS BY TECHNOLOGY 5. NEXT GENERATION SEQUENCING (NSG) MARKET ANALYSIS BY WORkFlOW 6. NEXT GENERATION SEQUENCING (NSG) MARKET ANALYSIS BY APPLICATION 7. NEXT GENERATION SEQUENCING (NSG) MARKET ANALYSIS BY END-USE 8. NEXT GENERATION SEQUENCING (NSG) MARKET ANALYSIS BY GEOGRAPHY 9. COMPETITIVE LANDSCAPE OF THE NEXT GENERATION SEQUENCING (NSG) COMPANIES 10. COMPANY PROFILES OF THE NEXT GENERATION SEQUENCING (NSG) INDUSTRY DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise and meaningful data at a lightning speed.


Patent
Macrogen Inc., Snu R&Db Foundation and Foundation University | Date: 2015-07-15

Provided is a fusion protein comprising AXL receptor tyrosine kinase (AXL protein) and MAP3K12 binding inhibitory protein 1 (MBIP protein), a composition for diagnosing a cancer comprising a substance interacting with the fusion protein, a method of providing information for diagnosing a cancer using the fusion protein, a composition for preventing and/or treating a cancer comprising an inhibitor against the fusion protein, and a method for screening an anticancer agent using the fusion protein.


News Article | November 14, 2016
Site: marketersmedia.com

— The report "Next-Generation Sequencing (NGS) Market by Platforms (HiSeq, MiSeq, HiSeq X Ten/X Five, Nextseq500, Ion Proton, PGM, IonS5, PacBio & Sequel), Services (Targeted Sequencing, De novo), & Application (Diagnostic, Drug Discovery) - Global Forecasts to 2021", The NGS market is expected to reach USD 10,371.1 Million by 2021 from USD 4,031.7 Million in 2016, at a CAGR of 20.8%. The report provides a detailed overview of the current trends and major drivers, restraints, opportunities, and challenges impacting the global NGS market along with the estimates and forecasts of the revenue and market share analysis. The global next generation sequencing market is poised to witness rapid growth between 2016 and 2021. Technological advancements in NGS products, increasing applications of NGS, entry of new market players, growing partnerships & collaborations among market players, and growing incidences of cancer, inherited rare disorders, and pre- and neo-natal disorders will majorly drive the NGS market. This report broadly segments the global next generation sequencing market into products & services, technology, application, and end user. The NGS market, by products & services is segmented into pre-sequencing products & services, NGS platforms, consumables, sequencing services, data analysis/bioinformatics. The pre-sequencing products & services segment if further categorized into DNA fragmentation. End repair, A-tailing, & size selection; library preparation & target enrichment; and quality control. The NGS platforms segment is sub-segmented into HiSeq Series, MiSeq Series, HiSeq X Ten & X Five, NextSeq500, Ion PGM, ION Proton, Ion S5 & S5 XL, PacBioRS II, and Sequel System. Based on applications, the sequencing services market is segmented into targeted sequencing, whole-genome sequencing, exome sequencing, RNA-Seq, De novo sequencing, Methyl-Seq, and ChiP-seq. On the basis of technology, the global next generation sequencing market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, sequencing by ligation (SBL), pyrosequencing, and single-molecule real-time (SMRT) sequencing. In 2016, the SBS technology is expected to account for the largest share of the global NGS market, by technology. Based on application, the global NGS market is segmented into diagnostics, drug discovery, biomarker discovery, personalized medicine, agriculture & animal research, and others (marine, forensic, & biofuel research). In 2016, the diagnostics application segment is expected to account for the largest share of the NGS market, by application. The end users of NGS market include research centers & academic/government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and others (non-profit organizations & agrigenomics organizations). In 2016, the research centers & academic/government institutes end user segment is expected to account for the largest share of the NGS market, by end user. This report covers the next generation sequencing market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to hold the largest share of this market in 2016, while Asia-Pacific is expected to grow at the fastest rate during the forecast period from 2016 to 2021. Improving healthcare infrastructure and favorable government initiatives in Asia-Pacific region is expected to drive the NGS market in this region. Illumina, Inc. (U.S.); Thermo Fisher Scientific, Inc. (U.S.); Pacific Biosciences of California, Inc. (U.S.); Roche Holding AG (Switzerland); QIAGEN N. V. (Germany); BGI (China), Macrogen Inc. (South Korea); Eurofins Scientific (Luxembourg); and Oxford Nanopore Technologies, Ltd. (U.K.) are the key players in the global NGS market. For more information, please visit http://www.marketsandmarkets.com/pdfdownload.asp?id=546


News Article | November 1, 2016
Site: www.prnewswire.co.uk

The global bioinformatics market is projected to reach USD 16.18 billion by 2021 from USD 6.21 billion in 2016, growing at a CAGR of 21.1% while led by the genomics segment with largest market share while North America to dominate the global bioinformatics market during forecast period. Complete report on bioinformatics market spread across 184 pages, profiling 10 companies and supported with 136 tables and 47 figures is now available at http://www.marketreportshub.com/bioinformatics-industry-research-marketsandmarkets.html . In this report, the bioinformatics market is broadly segmented on the basis of sector, products and services, application, and region. Factors such as the growing demand for nucleic acid and protein sequencing, increasing initiatives from government and private organizations, growing application of bioinformatics, and improved collaborative ties between companies and research institutes are driving the growth of the bioinformatics market. On the basis of sector, the bioinformatics market is categorized into medical biotechnology, academics, animal biotechnology, agricultural technology, environmental biotechnology, forensic biotechnology, and other sectors (homeland security and defense, law enforcement groups, bioweapon creation, and evolutionary biotechnology). In 2016, the medical biotechnology segment is expected to account for the largest share of the bioinformatics market. This growth can be attributed to the increasing use of bioinformatics in drug discovery and development processes for the faster development of safe and effective drugs at reduced costs. On the basis of application, the bioinformatics market has been segmented into genomics, chemoinformatics & drug design, proteomics, transcriptomics, metabolomics, molecular phylogenetics, and other applications (glycomics, cytomics, physiomics, and interactomics). North America is expected to account for the largest share of the bioinformatics market in 2016. Factors such as the increasing demand for bioinformatics across genomics and proteomics research, technological advancements, increasing research funding, and presence of a large number of market players and research institutes are propelling the growth of the market in North America. The APAC bioinformatics market is expected to register the highest CAGR of 22.3% in the next five years. Increasing research outsourcing to emerging countries by pharmaceutical giants for cost saving and increasing application of genomics in biotechnology and pharmaceutical research are contributing to the high growth of the APAC bioinformatics market during the forecast period. Product launches was the most widely adopted growth strategy pursued by players in the bioinformatics market. Major players operating in the bioinformatics market include Illumina Inc. (U.S.), Agilent Technologies (U.S.), and Thermo Fisher Scientific Inc. (U.S.), and QIAGEN N.V (Netherlands). Order a copy of Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 2021 research report at http://www.marketreportshub.com/purchase?rpid=1489 . On the basis of products and services, the bioinformatics market is categorized into knowledge management tools, bioinformatics platforms, and bioinformatics services. The knowledge management tools segment is expected to account for the largest market share in 2016. However, bioinformatics platforms are expected to grow at the highest CAGR during the forecast period; the growth of this segment is due to the reduction in overall time for processing data, phylogenetic analysis, and identification of sequence similarity On a related note, another research on Next-Generation Sequencing (NGS) Market Global Forecasts to 2021 says, the diagnostics application segment is expected to account for the largest share of the NGS market, by application. The research centers & academic/government institutes end user segment is to account for the largest shares, by end user. Overall market is to reach USD 10,371.1 Million by 2021 from USD 4,031.7 Million in 2016, at a CAGR of 20.8%. Companies like Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., Roche Holding AG, QIAGEN N. V., BGI, Macrogen Inc., Eurofins Scientific, and Oxford Nanopore Technologies, Ltd. have been profiled in this 208 pages research report available at http://www.marketreportshub.com/next-generation-sequencing-industry-research-marketsandmarkets.html . Explore more reports on life science market at http://www.marketreportshub.com/categories/life-sciences . Market Reports Hub is your one-stop online shop for syndicated industry research reports on 25+ categories and their sub-sectors. We bring to you to the latest in market research across multiple industries and geographies from leading research publishers across the globe.


Ju Y.S.,Seoul National University | Ju Y.S.,Macrogen Inc. | Lee W.-C.,Seoul National University | Shin J.-Y.,Seoul National University | And 11 more authors.
Genome Research | Year: 2012

The identification of the molecular events that drive cancer transformation is essential to the development of targeted agents that improve the clinical outcome of lung cancer. Many studies have reported genomic driver mutations in non-small-cell lung cancers (NSCLCs) over the past decade; however, the molecular pathogenesis of >40%of NSCLCs is still unknown. To identify new molecular targets in NSCLCs, we performed the combined analysis of massively parallel whole-genome and transcriptome sequencing for cancer and paired normal tissue of a 33-yr-old lung adenocarcinoma patient, who is a never-smoker and has no familial cancer history. The cancer showed no known driver mutation in EGFR or KRAS and no EML4-ALK fusion. Here we report a novel fusion gene between KIF5B and the RET proto-oncogene caused by a pericentric inversion of 10p11.22-q11.21. This fusion gene overexpresses chimeric RET receptor tyrosine kinase, which could spontaneously induce cellular transformation. We identified the KIF5B-RET fusion in two more cases out of 20 primary lung adenocarcinomas in the replication study.Our data demonstrate that a subset ofNSCLCs could be caused by a fusion of KIF5B and RET, andsuggest the chimeric oncogene as a promising molecular target for the personalized diagnosis and treatment of lung cancer. © 2012 by Cold Spring Harbor Laboratory Press.


Patent
Macrogen Inc. | Date: 2010-09-15

A diagnostic technology for breast cancer, in particular, caused by Her-2 copy number variation is provided. Said diagnostic technology identifies the amplification attributable to Her-2 copy number variations and thus allows correct, convenient and rapid diagnosis of breast cancer caused by the amplification attributable to Her-2 copy number variations. As such, said diagnostic technology is highly beneficial for customized treatments of breast cancer such as the therapy using Her-2 antibody (e.g. Herceptin).


Disclosed is the biological production of lactic acid using a microorganism. A transformant capable of producing lactic acid of high optical purity at high yield, a method for the preparation thereof, and a method for producing lactic acid in a convenient and economically beneficial manner using the same are provided. The Zymomonas mobilis transformant can produce lactic acid of high optical purity at high yield without a stringent limitation to production conditions and a regulation of the intracellular metabolism pathway. Because it requires no additional separation and purification steps, the use of the transformant allows the production of lactic acid in a short process, resulting in a significant reduction in production cost, and avoiding the environment problems caused by precipitate wastes, which brings about environmental issues.


Patent
Macrogen Inc. | Date: 2012-12-26

A genetic information managing apparatus compares a base sequence of a subject with a standard base sequence to determine a longest common base sequence, and arranges the base sequence of the subject on the standard base sequence in accordance with the longest common base sequence. The genetic information managing apparatus divides the arranged base sequence into a plurality of base code groups, allocates a plurality of identifiers to the plurality of base code groups, respectively, and stores the plurality of base code groups to a plurality of storing units in association with corresponding identifiers.


Disclosed is the biological production of lactic acid using a microorganism. A transformant capable of producing lactic acid of high optical purity at high yield, a method for the preparation thereof, and a method for producing lactic acid in a convenient and economically beneficial manner using the same are provided. The Zymomonas mobilis transformant can produce lactic acid of high optical purity at high yield without a stringent limitation to production conditions and a regulation of the intracellular metabolism pathway. Because it requires no additional separation and purification steps, the use of the transformant allows the production of lactic acid in a short process, resulting in a significant reduction in production cost, and avoiding the environment problems caused by precipitate wastes, which brings about environmental issues.


A fusion protein including N-terminal domain of a fusion partner at N-terminal and C-terminal domain of RET protein at C-terminal, a fusion gene encoding the fusion protein, and a use of the fusion protein or the fusion gene as a diagnosing marker for a cancer, are provided.

Loading Macrogen Inc. collaborators
Loading Macrogen Inc. collaborators